Skip to content
2000
Volume 22, Issue 1
  • ISSN: 2666-0822
  • E-ISSN: 2666-0830

Abstract

The correlation between elevated levels of amyloid-β and phosphorylated tau (p-tau) protein and AD is widely recognized. A rise in pTau and amyloid-β levels aids in separating AD from other neurodegenerative conditions. In this study, we have assessed the correlation between cognitive impairment and peripheral biomarkers, tau and amyloid-β levels, in AD patients with mild Alzheimer's disease in order to develop protein-based markers in a more useful way. An enzyme-linked immunosorbent assay has been used to determine the levels of tau and p-tau in the serum of the different groups and it has revealed their levels to be noticeably greater in AD compared to mild AD and even higher compared to elderly controls. Based on the cutoff levels for tau, p-tau, and amyloid-β in patients with AD and mild AD, having high sensitivity and specificity, which have been described in numerous studies by respective International Research Groups (with the greatest number of pieces of available evidence), the plasma concentration of these proteins can be used as a diagnostic indicator for AD and mild AD. These levels may also offer a practical guide to their implementation in the clinical routine.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cprr/10.2174/0126660822329981241007105405
2024-10-16
2026-02-28

  • From This Site

    /content/journals/cprr/10.2174/0126660822329981241007105405
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HampelH. BlennowK. ShawL.M. HoesslerY.C. ZetterbergH. TrojanowskiJ.Q. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease.Exp. Gerontol.2010451304010.1016/j.exger.2009.10.01019853650
     [Google Scholar]
  2. AndreasenN. MinthonL. ClarbergA. DavidssonP. GottfriesJ. VanmechelenE. VandersticheleH. WinbladB. BlennowK. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.Neurology19995371488149410.1212/WNL.53.7.148810534256
     [Google Scholar]
  3. Gómez-TortosaE. GonzaloI. FanjulS. SainzM.J. CantareroS. CemillánC. YébenesJ.G. del SerT. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.Arch. Neurol.20036091218122210.1001/archneur.60.9.121812975286
     [Google Scholar]
  4. HampelH. BürgerK. PruessnerJ.C. ZinkowskiR. DeBernardisJ. KerkmanD. LeinsingerG. EvansA.C. DaviesP. MöllerH.J. TeipelS.J. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease.Arch. Neurol.200562577077310.1001/archneur.62.5.77015883264
     [Google Scholar]
  5. NäggaK. GottfriesJ. BlennowK. MarcussonJ. Cerebrospinal fluid phospho-tau, total tau and β-amyloid(1-42) in the differentiation between Alzheimer’s disease and vascular dementia.Dement. Geriatr. Cogn. Disord.200214418319010.1159/00006602312411760
     [Google Scholar]
  6. SchneiderP. HampelH. BuergerK. Biological marker candidates of Alzheimer’s disease in blood, plasma, and serum.CNS Neurosci. Ther.200915435837410.1111/j.1755‑5949.2009.00104.x19840034
     [Google Scholar]
  7. SchoonenboomN.S.M. PijnenburgY.A.L. MulderC. RossoS.M. Van ElkE.J. Van KampG.J. Van SwietenJ.C. ScheltensP. Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.Neurology20046291580158410.1212/01.WNL.0000123249.58898.E015136685
     [Google Scholar]
  8. ShawL.M. KoreckaM. ClarkC.M. LeeV.M.Y. TrojanowskiJ.Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.Nat. Rev. Drug Discov.20076429530310.1038/nrd217617347655
     [Google Scholar]
  9. ShawL.M. VandersticheleH. Knapik-CzajkaM. ClarkC.M. AisenP.S. PetersenR.C. BlennowK. SoaresH. SimonA. LewczukP. DeanR. SiemersE. PotterW. LeeV.M.Y. TrojanowskiJ.Q. Alzheimer’s Disease Neuroimaging Initiative Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects.Ann. Neurol.200965440341310.1002/ana.2161019296504
     [Google Scholar]
  10. VillaC. LavitranoM. SalvatoreE. CombiR. Molecular and imaging biomarkers in Alzheimer’s disease: A focus on recent insights.J. Pers. Med.20201036110.3390/jpm1003006132664352
     [Google Scholar]
  11. BatemanR.J. XiongC. BenzingerT.L.S. FaganA.M. GoateA. FoxN.C. MarcusD.S. CairnsN.J. XieX. BlazeyT.M. HoltzmanD.M. SantacruzA. BucklesV. OliverA. MoulderK. AisenP.S. GhettiB. KlunkW.E. McDadeE. MartinsR.N. MastersC.L. MayeuxR. RingmanJ.M. RossorM.N. SchofieldP.R. SperlingR.A. SallowayS. MorrisJ.C. Dominantly Inherited Alzheimer Network Clinical and biomarker changes in dominantly inherited Alzheimer’s disease.N. Engl. J. Med.2012367979580410.1056/NEJMoa120275322784036
     [Google Scholar]
  12. WeintraubS. WicklundA.H. SalmonD.P. The neuropsychological profile of Alzheimer disease.Cold Spring Harb. Perspect. Med.201224a00617110.1101/cshperspect.a00617122474609
     [Google Scholar]
  13. WilliamsD.R. de SilvaR. PaviourD.C. PittmanA. WattH.C. KilfordL. HoltonJ.L. ReveszT. LeesA.J. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism.Brain200512861247125810.1093/brain/awh48815788542
     [Google Scholar]
  14. OuteiroT.F. KossD.J. ErskineD. WalkerL. Kurzawa-AkanbiM. BurnD. DonaghyP. MorrisC. TaylorJ.P. ThomasA. AttemsJ. McKeithI. Dementia with Lewy bodies: An update and outlook.Mol. Neurodegener.2019141510.1186/s13024‑019‑0306‑830665447
     [Google Scholar]
  15. SlatteryC.F. CrutchS.J. SchottJ.M. Phenotypical variation in Alzheimer’s disease: Insights from posterior cortical atrophy.Pract. Neurol.20151512410.1136/practneurol‑2014‑00095525239627
     [Google Scholar]
  16. VermuntL. SikkesS.A.M. van den HoutA. HandelsR. BosI. van der FlierW.M. KernS. OussetP.J. MaruffP. SkoogI. VerheyF.R.J. Freund-LeviY. TsolakiM. WallinÅ.K. Olde RikkertM. SoininenH. SpiruL. ZetterbergH. BlennowK. ScheltensP. Muniz-TerreraG. VisserP.J. Alzheimer Disease Neuroimaging Initiative AIBL Research Group ICTUS/DSA study groups Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype.Alzheimers Dement.201915788889810.1016/j.jalz.2019.04.00131164314
     [Google Scholar]
  17. AusóE. Gómez-VicenteV. EsquivaG. Biomarkers for Alzheimer’s disease early diagnosis.J. Pers. Med.202010311410.3390/jpm1003011432899797
     [Google Scholar]
  18. Sheikh-BahaeiN. SajjadiS.A. ManavakiR. GillardJ.H. Imaging biomarkers in Alzheimer’s disease: A practical guide for clinicians.J. Alzheimers Dis. Rep.201711718810.3233/ADR‑17001330480230
     [Google Scholar]
  19. McGrowderD.A. MillerF. VazK. NwokochaC. Wilson-ClarkeC. Anderson-CrossM. BrownJ. Anderson-JacksonL. WilliamsL. LatoreL. ThompsonR. Alexander-LindoR. Cerebrospinal fluid biomarkers of Alzheimer’s disease: Current evidence and future perspectives.Brain Sci.202111221510.3390/brainsci1102021533578866
     [Google Scholar]
  20. TeunissenC.E. VerberkI.M.W. ThijssenE.H. VermuntL. HanssonO. ZetterbergH. van der FlierW.M. MielkeM.M. del CampoM. Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation.Lancet Neurol.2022211667710.1016/S1474‑4422(21)00361‑634838239
     [Google Scholar]
  21. SjögrenM. MinthonL. DavidssonP. GranérusA-K. ClarbergA. VandersticheleH. VanmechelenE. WallinA. BlennowK. CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging.J. Neural Transm.2000107556357910.1007/s00702007007911072752
     [Google Scholar]
  22. WelgeV. FiegeO. LewczukP. MollenhauerB. EsselmannH. KlafkiH.W. WolfS. TrenkwalderC. OttoM. KornhuberJ. WiltfangJ. BiblM. Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease.J. Neural Transm.2009116220321210.1007/s00702‑008‑0177‑619142572
     [Google Scholar]
  23. VemuriP. WisteH.J. WeigandS.D. ShawL.M. TrojanowskiJ.Q. WeinerM.W. KnopmanD.S. PetersenR.C. JackC.R.Jr Alzheimer’s Disease Neuroimaging Initiative MRI and CSF biomarkers in normal, MCI, and AD subjects.Neurology200973428729310.1212/WNL.0b013e3181af79e519636048
     [Google Scholar]
  24. ShekharS. KumarR. RaiN. KumarV. SinghK. UpadhyayA.D. TripathiM. DwivediS. DeyA.B. DeyS. Estimation of tau and phosphorylated tau181 in serum of Alzheimer’s disease and mild cognitive impairment patients.PLoS One2016117e015909910.1371/journal.pone.015909927459603
     [Google Scholar]
  25. BlennowK. HampelH. WeinerM. ZetterbergH. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.Nat. Rev. Neurol.20106313114410.1038/nrneurol.2010.420157306
     [Google Scholar]
  26. TapiolaT. AlafuzoffI. HerukkaS.K. ParkkinenL. HartikainenP. SoininenH. PirttiläT. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.Arch. Neurol.200966338238910.1001/archneurol.2008.59619273758
     [Google Scholar]
  27. IrizarryM.C. Biomarkers of Alzheimer disease in plasma.NeuroRx20041222623410.1602/neurorx.1.2.22615717023
     [Google Scholar]
  28. MedeirosR. Baglietto-VargasD. LaFerlaF.M. The role of tau in Alzheimer’s disease and related disorders.CNS Neurosci. Ther.201117551452410.1111/j.1755‑5949.2010.00177.x20553310
     [Google Scholar]
  29. GaoY. TanL. YuJ.T. TanL. Tau in Alzheimer’s disease: Mechanisms and therapeutic strategies.Curr. Alzheimer Res.201815328330010.2174/156720501466617041711185928413986
     [Google Scholar]
  30. YoshiyamaY. LeeV.M.Y. TrojanowskiJ.Q. Therapeutic strategies for tau mediated neurodegeneration.J. Neurol. Neurosurg. Psychiatry201384778479510.1136/jnnp‑2012‑30314423085937
     [Google Scholar]
  31. LiuH. WangL. SuW. XieX.Q. Advances in recent patent and clinical trial drug development for Alzheimer’s disease.Pharm. Pat. Anal.20143442944710.4155/ppa.14.2225291315
     [Google Scholar]
  32. IqbalK. LiuF. GongC.X. Grundke-IqbalI. Tau in Alzheimer disease and related tauopathies.Curr. Alzheimer Res.20107865666410.2174/15672051079361159220678074
     [Google Scholar]
  33. QuintanillaR.A. OrellanaD.I. González-BillaultC. MaccioniR.B. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway.Exp. Cell Res.2004295124525710.1016/j.yexcr.2004.01.00215051507
     [Google Scholar]
  34. NobleW. OlmV. TakataK. CaseyE. MaryO. MeyersonJ. GaynorK. LaFrancoisJ. WangL. KondoT. DaviesP. BurnsM. Veeranna NixonR. DicksonD. MatsuokaY. AhlijanianM. LauL.F. DuffK. Cdk5 is a key factor in tau aggregation and tangle formation in vivo.Neuron200338455556510.1016/S0896‑6273(03)00259‑912765608
     [Google Scholar]
  35. AndreasenN. MinthonL. DavidssonP. VanmechelenE. VandersticheleH. WinbladB. BlennowK. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.Arch. Neurol.200158337337910.1001/archneur.58.3.37311255440
     [Google Scholar]
  36. BuergerK. FrisoniG. UspenskayaO. EwersM. ZetterbergH. GeroldiC. BinettiG. JohannsenP. RossiniP.M. WahlundL.O. VellasB. BlennowK. HampelH. Validation of Alzheimer’s disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI).Exp. Gerontol.200944957958510.1016/j.exger.2009.06.00319539742
     [Google Scholar]
  37. EwersM. MielkeM.M. HampelH. Blood-based biomarkers of microvascular pathology in Alzheimer’s disease.Exp. Gerontol.2010451757910.1016/j.exger.2009.09.00519782124
     [Google Scholar]
  38. FrankR.A. GalaskoD. HampelH. HardyJ. de LeonM.J. MehtaP.D. RogersJ. SiemersE. TrojanowskiJ.Q. National Institute on Aging Biological Markers Working Group Biological markers for therapeutic trials in Alzheimer’s disease.Neurobiol. Aging200324452153610.1016/S0197‑4580(03)00002‑212714109
     [Google Scholar]
  39. HampelH. HardyJ. BlennowK. ChenC. PerryG. KimS.H. VillemagneV.L. AisenP. VendruscoloM. IwatsuboT. MastersC.L. ChoM. LannfeltL. CummingsJ.L. VergalloA. Vendruscolo, Iwatsubo T, Masters CL. The amyloid-β pathway in Alzheimer’s disease.Mol. Psychiatry202126105481550310.1038/s41380‑021‑01249‑034456336
     [Google Scholar]
  40. KummerM.P. HenekaM.T. Truncated and modified amyloid-beta species.Alzheimers Res. Ther.2014632810.1186/alzrt25825031638
     [Google Scholar]
  41. TosiG. PederzoliF. BellettiD. VandelliM.A. ForniF. DuskeyJ.T. RuoziB. Nanomedicine in Alzheimer’s disease: Amyloid beta targeting strategy.Prog. Brain Res.2019245578810.1016/bs.pbr.2019.03.00130961872
     [Google Scholar]
  42. HampelH. TeipelS.J. FuchsbergerT. AndreasenN. WiltfangJ. OttoM. ShenY. DodelR. DuY. FarlowM. MöllerH-J. BlennowK. BuergerK. Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment.Mol. Psychiatry20049770571010.1038/sj.mp.400147314699432
     [Google Scholar]
  43. HampelH. BroichK. HoesslerY. PantelJ. Biological markers for early detection and pharmacological treatment of Alzheimer’s disease.Dialogues Clin. Neurosci.202210.31887/DCNS.2009.11.2/hhampel19585950
     [Google Scholar]
  44. HampelH. ShenY. WalshD.M. AisenP. ShawL.M. ZetterbergH. TrojanowskiJ.Q. BlennowK. Biological markers of amyloid β-related mechanisms in Alzheimer’s disease.Exp. Neurol.2010223233434610.1016/j.expneurol.2009.09.02419815015
     [Google Scholar]
  45. PyunJ.M. YounY.C. ParkY.H. KimS. Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer’s disease diagnosis.Front. Neurol.202313102844810.3389/fneur.2022.102844836733444
     [Google Scholar]
  46. ChenY. YuY. Tau and neuroinflammation in Alzheimer’s disease: Interplay mechanisms and clinical translation.J. Neuroinflammation202320116510.1186/s12974‑023‑02853‑337452321
     [Google Scholar]
  47. HammondT.C. XingX. WangC. MaD. NhoK. CraneP.K. ElahiF. ZieglerD.A. LiangG. ChengQ. YanckelloL.M. JacobsN. LinA.L. β-amyloid and tau drive early Alzheimer’s disease decline while glucose hypometabolism drives late decline.Commun. Biol.20203135210.1038/s42003‑020‑1079‑x32632135
     [Google Scholar]
  48. ZhangW. XiaoD. MaoQ. XiaH. Role of neuroinflammation in neurodegeneration development.Signal Transduct. Target. Ther.20238126710.1038/s41392‑023‑01486‑537433768
     [Google Scholar]
  49. d’ErricoP. Meyer-LuehmannM. Mechanisms of pathogenic tau and Aβ protein spreading in Alzheimer’s disease.Front. Aging Neurosci.20201226510.3389/fnagi.2020.0026533061903
     [Google Scholar]
  50. KlyucherevT.O. OlszewskiP. ShalimovaA.A. ChubarevV.N. TarasovV.V. AttwoodM.M. SyvänenS. SchiöthH.B. Advances in the development of new biomarkers for Alzheimer’s disease.Transl. Neurodegener.20221112510.1186/s40035‑022‑00296‑z35449079
     [Google Scholar]
  51. TuS. OkamotoS. LiptonS.A. XuH. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease.Mol. Neurodegener.2014914810.1186/1750‑1326‑9‑4825394486
     [Google Scholar]
  52. AlonsoA.D. CohenL.S. CorboC. MorozovaV. ElIdrissiA. PhillipsG. KleimanF.E. Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability.Front. Cell. Neurosci.20181233810.3389/fncel.2018.0033830356756
     [Google Scholar]
  53. KanaanN.M. PiginoG.F. BradyS.T. LazarovO. BinderL.I. MorfiniG.A. Axonal degeneration in Alzheimer’s disease: When signaling abnormalities meet the axonal transport system.Exp. Neurol.2013246445310.1016/j.expneurol.2012.06.00322721767
     [Google Scholar]
  54. ZilkaN. FilipcikP. KosonP. FialovaL. SkrabanaR. ZilkovaM. RolkovaG. KontsekovaE. NovakM. Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo.FEBS Lett.2006580153582358810.1016/j.febslet.2006.05.02916753151
     [Google Scholar]
  55. RobbinsM. ClaytonE. Kaminski SchierleG.S. Synaptic tau: A pathological or physiological phenomenon?Acta Neuropathol. Commun.20219114910.1186/s40478‑021‑01246‑y34503576
     [Google Scholar]
  56. Cárdenas-AguayoM.C. Gómez-VirgilioL. DeRosaS. Meraz-RíosM.A. The role of tau oligomers in the onset of Alzheimer’s disease neuropathology.ACS Chem. Neurosci.20145121178119110.1021/cn500148z25268947
     [Google Scholar]
  57. BuscheM.A. HymanB.T. Synergy between amyloid-β and tau in Alzheimer’s disease.Nat. Neurosci.202023101183119310.1038/s41593‑020‑0687‑632778792
     [Google Scholar]
  58. JiaJ.P. MengR. SunY.X. SunW.J. JiX.M. JiaL.F. Cerebrospinal fluid tau, Aβ1–42 and inflammatory cytokines in patients with Alzheimer’s disease and vascular dementia.Neurosci. Lett.20053831-2121610.1016/j.neulet.2005.03.05115936505
     [Google Scholar]
  59. LewczukP. EsselmannH. OttoM. MalerJ.M. HenkelA.W. HenkelM.K. EikenbergO. AntzC. KrauseW.R. ReulbachU. KornhuberJ. WiltfangJ. Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau.Neurobiol. Aging200425327328110.1016/S0197‑4580(03)00086‑115123331
     [Google Scholar]
  60. ShojiM. MatsubaraE. KanaiM. WatanabeM. NakamuraT. TomidokoroY. ShizukaM. WakabayashiK. IgetaY. IkedaY. MizushimaK. AmariM. IshiguroK. KawarabayashiT. HarigayaY. OkamotoK. HiraiS. Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer’s disease.J. Neurol. Sci.1998158213414010.1016/S0022‑510X(98)00122‑19702683
     [Google Scholar]
  61. AshiqueS. SirohiE. KumarS. RihanM. MishraN. BhattS. GautamR.K. SinghS.K. GuptaG. ChellappanD.K. DuaK. Aducanumab in Alzheimer’s disease: A critical update.Curr. Med. Chem.202310.2174/092986733166623072710355337497712
     [Google Scholar]
  62. SunderlandT. LinkerG. MirzaN. PutnamK.T. FriedmanD.L. KimmelL.H. BergesonJ. ManettiG.J. ZimmermannM. TangB. BartkoJ.J. CohenR.M. Decreased β-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.JAMA2003289162094210310.1001/jama.289.16.209412709467
     [Google Scholar]
  63. DicksonD.W. CrystalH.A. BevonaC. HonerW. VincentI. DaviesP. Correlations of synaptic and pathological markers with cognition of the elderly.Neurobiol. Aging199516328529810.1016/0197‑4580(95)00013‑57566338
     [Google Scholar]
  64. HimmlerA. DrechselD. KirschnerM.W. MartinD.W.Jr Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains.Mol. Cell. Biol.1989941381138810.1128/mcb.9.4.1381‑1388.19892498649
     [Google Scholar]
  65. AndreadisA. Tau gene alternative splicing: Expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases.Biochim. Biophys. Acta Mol. Basis Dis.200517392-39110310.1016/j.bbadis.2004.08.01015615629
     [Google Scholar]
  66. HongM. ZhukarevaV. Vogelsberg-RagagliaV. WszolekZ. ReedL. MillerB.I. GeschwindD.H. BirdT.D. McKeelD. GoateA. MorrisJ.C. WilhelmsenK.C. SchellenbergG.D. TrojanowskiJ.Q. LeeV.M. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.Science199828253951914191710.1126/science.282.5395.19149836646
     [Google Scholar]
  67. BrionJ.P. OctaveJ.N. CouckA.M. Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neurons.Neuroscience199463389590910.1016/0306‑4522(94)90533‑97898684
     [Google Scholar]
  68. HangerD.P. GibbG.M. de SilvaR. BoutajangoutA. BrionJ.P. ReveszT. LeesA.J. AndertonB.H. The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies.FEBS Lett.2002531353854210.1016/S0014‑5793(02)03611‑612435607
     [Google Scholar]
  69. LathuilièreA. ValdésP. PapinS. CacquevelM. MaclachlanC. KnottG.W. MuhsA. PaganettiP. SchneiderB.L. Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects.Sci. Rep.2017711355610.1038/s41598‑017‑13786‑229051562
     [Google Scholar]
  70. YenS.H. More thoughts on plaques and tangles.Neurobiol. Aging19867643243410.1016/0197‑4580(86)90056‑43561656
     [Google Scholar]
  71. SamanS. KimW. RayaM. VisnickY. MiroS. SamanS. JacksonB. McKeeA.C. AlvarezV.E. LeeN.C.Y. HallG.F. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.J. Biol. Chem.201228763842384910.1074/jbc.M111.27706122057275
     [Google Scholar]
  72. FiandacaM.S. KapogiannisD. MapstoneM. BoxerA. EitanE. SchwartzJ.B. AbnerE.L. PetersenR.C. FederoffH.J. MillerB.L. GoetzlE.J. Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case‐control study.Alzheimers Dement.20151166007.e110.1016/j.jalz.2014.06.00825130657
     [Google Scholar]
  73. BrandtR. LégerJ. LeeG. Interaction of tau with the neural plasma membrane mediated by tau’s amino-terminal projection domain.J. Cell Biol.199513151327134010.1083/jcb.131.5.13278522593
     [Google Scholar]
  74. SantaCruzK. LewisJ. SpiresT. PaulsonJ. KotilinekL. IngelssonM. GuimaraesA. DeTureM. RamsdenM. McGowanE. ForsterC. YueM. OrneJ. JanusC. MariashA. KuskowskiM. HymanB. HuttonM. AsheK.H. Tau suppression in a neurodegenerative mouse model improves memory function.Science2005309573347648110.1126/science.111369416020737
     [Google Scholar]
  75. Martinez-CoriaH. GreenK.N. BillingsL.M. KitazawaM. AlbrechtM. RammesG. ParsonsC.G. GuptaS. BanerjeeP. LaFerlaF.M. Memantine improves cognition and reduces Alzheimer’s-like neuropathology in transgenic mice.Am. J. Pathol.2010176287088010.2353/ajpath.2010.09045220042680
     [Google Scholar]
  76. SmithM.A. SiedlakS.L. RicheyP.L. MulvihillP. GhisoJ. FrangioneB. TagliaviniF. GiacconeG. BugianiO. PraprotnikD. KalariaR.N. PerryG. Tau protein directly interacts with the amyloid β-protein precursor: Implications for Alzheimer’s disease.Nat. Med.19951436536910.1038/nm0495‑3657585068
     [Google Scholar]
  77. NobleW. PlanelE. ZehrC. OlmV. MeyersonJ. SulemanF. GaynorK. WangL. LaFrancoisJ. FeinsteinB. BurnsM. KrishnamurthyP. WenY. BhatR. LewisJ. DicksonD. DuffK. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo .Proc. Natl. Acad. Sci. USA2005102196990699510.1073/pnas.050046610215867159
     [Google Scholar]
  78. ZetterbergH. WilsonD. AndreassonU. MinthonL. BlennowK. RandallJ. HanssonO. Plasma tau levels in Alzheimer’s disease.Alzheimers Res. Ther.201352910.1186/alzrt16323551972
     [Google Scholar]
  79. GanguliM. RatcliffG. ChandraV. SharmaS. GilbyJ. PandavR. BelleS. RyanC. BakerC. SeabergE. DekoskyS. A hindi version of the MMSE: The development of a cognitive screening instrument for a largely illiterate rural elderly population in india.Int. J. Geriatr. Psychiatry199510536737710.1002/gps.930100505
     [Google Scholar]
  80. BrundenK.R. TrojanowskiJ.Q. LeeV.M.Y. Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies.Nat. Rev. Drug Discov.200981078379310.1038/nrd295919794442
     [Google Scholar]
  81. DarstB. F. KoscikR. L. RacineA. M. OhJ. M. KrauseR. A. CarlssonC. M. ZetterbergH. BlennowK. ChristianB. T. BendlinB. B. OkonkwoO. C. HoganK. J. HermannB. P. SagerM. A. AsthanaS. JohnsonS. C. EngelmanC. D. Pathway-specific polygenic risk scores as predictors of amyloid-β deposition and cognitive function in a sample at increased risk for alzheimer's disease.J. Alzheimers Dis.201755247348410.3233/JAD‑160195
     [Google Scholar]
  82. RembachA. WattA.D. WilsonW.J. VillemagneV.L. BurnhamS.C. EllisK.A. MaruffP. AmesD. RoweC.C. MacaulayS.L. BushA.I. MartinsR.N. MastersC.L. DoeckeJ.D. AIBL Research Group Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden.J. Alzheimers Dis.20144019510410.3233/JAD‑13180224334723
     [Google Scholar]
  83. ButterfieldD.A. DrakeJ. PocernichC. CastegnaA. Evidence of oxidative damage in Alzheimer’s disease brain: Central role for amyloid β-peptide.Trends Mol. Med.200171254855410.1016/S1471‑4914(01)02173‑611733217
     [Google Scholar]
  84. ZouK. AbdullahM. MichikawaM. Current biomarkers for alzheimer’s disease: From CSF to blood.J. Pers. Med.20201038510.3390/jpm1003008532806668
     [Google Scholar]
  85. KimH.J. LimT.S. LeeS.M. KimT.S. KimY. AnY.S. YounY.C. ParkS.A. ChangJ. MoonS.Y. Cerebrospinal fluid levels of β-amyloid 40 and β-amyloid 42 are proportionately decreased in amyloid positron-emission tomography negative idiopathic normal-pressure hydrocephalus patients.J. Clin. Neurol.201915335335910.3988/jcn.2019.15.3.35331286708
     [Google Scholar]
  86. CullenN. JanelidzeS. PalmqvistS. StomrudE. Mattsson-CarlgrenN. HanssonO. Alzheimer’s Disease Neuroimaging Initiative Association of CSF Aβ 38 levels with risk of alzheimer disease–related decline.Neurology2022989e958e96710.1212/WNL.000000000001322834937781
     [Google Scholar]
  87. HabibA. SawmillerD. TanJ. Restoring soluble amyloid precursor protein α functions as a potential treatment for >Alzheimer’s disease.J. Neurosci. Res.201795497399110.1002/jnr.2382327531392
     [Google Scholar]
  88. PerneczkyR. GuoL-H. KagerbauerS.M. WerleL. KurzA. MartinJ. AlexopoulosP. Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer’s disease.Transl. Psychiatry201332e22710.1038/tp.2013.1123423136
     [Google Scholar]
  89. Gonzalez-OrtizF. KacP.R. BrumW.S. ZetterbergH. BlennowK. KarikariT.K. Plasma phospho-tau in Alzheimer’s disease: Towards diagnostic and therapeutic trial applications.Mol. Neurodegener.20231811810.1186/s13024‑023‑00605‑836927491
     [Google Scholar]
  90. MielkeM.M. SyrjanenJ.A. BlennowK. ZetterbergH. VemuriP. SkoogI. MachuldaM.M. KremersW.K. KnopmanD.S. JackC.Jr PetersenR.C. KernS. Plasma and CSF neurofilament light.Neurology2019933e252e26010.1212/WNL.000000000000776731182505
     [Google Scholar]
  91. SchmidtF.M. MerglR. StachB. JahnI. GertzH.J. SchönknechtP. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer’s disease.Neurosci. Lett.2014570818510.1016/j.neulet.2014.04.00724746933
     [Google Scholar]
  92. TarawnehR. D’AngeloG. MacyE. XiongC. CarterD. CairnsN.J. FaganA.M. HeadD. MintunM.A. LadensonJ.H. LeeJ.M. MorrisJ.C. HoltzmanD.M. Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease.Ann. Neurol.201170227428510.1002/ana.2244821823155
     [Google Scholar]
  93. OlssonB. HertzeJ. OhlssonM. NäggaK. HöglundK. BasunH. AnnasP. LannfeltL. AndreasenN. MinthonL. ZetterbergH. BlennowK. HanssonO. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer’s disease and vascular dementia.J. Alzheimers Dis.201334367367910.3233/JAD‑12138423254629
     [Google Scholar]
  94. SkillbäckT. DelsingL. SynnergrenJ. MattssonN. JanelidzeS. NäggaK. KilanderL. HicksR. WimoA. WinbladB. HanssonO. BlennowK. EriksdotterM. ZetterbergH. CSF/serum albumin ratio in dementias: A cross-sectional study on 1861 patients.Neurobiol. Aging2017591910.1016/j.neurobiolaging.2017.06.02828779628
     [Google Scholar]
  95. MavroudisI. ChowdhuryR. PetridisF. KarantaliE. ChatzikonstantinouS. BalmusI.M. LucaI.S. CiobicaA. KazisD. YKL-40 as a potential biomarker for the differential diagnosis of alzheimer’s disease.Medicina20215816010.3390/medicina5801006035056368
     [Google Scholar]
  96. LeeW.J. LiaoY.C. WangY.F. LinI.F. WangS.J. FuhJ.L. Plasma MCP-1 and cognitive decline in patients with alzheimer’s disease and mild cognitive impairment: A two-year follow-up study.Sci. Rep.201881128010.1038/s41598‑018‑19807‑y29352259
     [Google Scholar]
  97. KimK.Y. ShinK.Y. ChangK.A. GFAP as a potential biomarker for alzheimer’s disease: A systematic review and meta-analysis.Cells2023129130910.3390/cells1209130937174709
     [Google Scholar]
  98. SaundersT. GunnC. BlennowK. KvartsbergH. ZetterbergH. ShenkinS.D. CoxS.R. DearyI.J. SmithC. KingD. Spires-JonesT. Neurogranin in Alzheimer’s disease and ageing: A human post- mortem study.Neurobiol. Dis.202317710599110.1016/j.nbd.2023.10599136623608
     [Google Scholar]
  99. OharaT. HataJ. TanakaM. HondaT. YamakageH. YoshidaD. InoueT. HirakawaY. KusakabeT. ShibataM. TeraokaT. KitazonoT. KanbaS. Satoh-AsaharaN. NinomiyaT. Serum soluble triggering receptor expressed on myeloid cells 2 as a biomarker for incident dementia: The hisayama study.Ann. Neurol.2019851475810.1002/ana.2538530485483
     [Google Scholar]
  100. HendersonM.X. TrojanowskiJ.Q. LeeV.M.Y. α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies.Neurosci. Lett.201970913431610.1016/j.neulet.2019.13431631170426
     [Google Scholar]
  101. HampelH. ShenY. Beta‐site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer’s disease.Scand. J. Clin. Lab. Invest.200969181210.1080/0036551070186461018609117
     [Google Scholar]
  102. YounY.C. LeeB.S. KimG.J. RyuJ.S. LimK. LeeR. SuhJ. ParkY.H. PyunJ.M. RyuN. KangM.J. KimH.R. KangS. AnS.S.A. KimS. Blood amyloid-β oligomerization as a biomarker of alzheimer’s disease: A blinded validation study.J. Alzheimers Dis.202075249349910.3233/JAD‑20006132310175
     [Google Scholar]
  103. KumarR. KumarR. SharmaN. KhuranaN. SinghS.K. SatijaS. MehtaM. VyasM. Pharmacological evaluation of bromelain in mouse model of Alzheimer’s disease.Neurotoxicology202290193410.1016/j.neuro.2022.02.00935219781
     [Google Scholar]
  104. DelabyC. HirtzC. LehmannS. Overview of the blood biomarkers in Alzheimer’s disease: Promises and challenges.Rev. Neurol.2023179316117210.1016/j.neurol.2022.09.00336371265
     [Google Scholar]
  105. AttiaM.F. AntonN. WallynJ. OmranZ. VandammeT.F. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites.J. Pharm. Pharmacol.20197181185119810.1111/jphp.1309831049986
     [Google Scholar]
  106. HuangJ. HuangN. MaoQ. ShiJ. QiuY. Natural bioactive compounds in Alzheimer’s disease: From the perspective of type 3 diabetes mellitus.Front. Aging Neurosci.202315113025310.3389/fnagi.2023.113025337009462
     [Google Scholar]
  107. VrahatisA.G. SkolarikiK. KrokidisM.G. LazarosK. ExarchosT.P. VlamosP. Revolutionizing the early detection of alzheimer’s disease through non-invasive biomarkers: The role of artificial intelligence and deep learning.Sensors2023239418410.3390/s2309418437177386
     [Google Scholar]
  108. ReusL.M. VijverbergE.G.B. TijmsB.M. KateM. GossinkF. KrudopW.A. CampoM. TeunissenC.E. BarkhofF. van der FlierW.M. VisserP.J. DolsA. PijnenburgY.A.L. Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change.J. Psychiatr. Res.201810418319110.1016/j.jpsychires.2018.07.01430103065
     [Google Scholar]
  109. JansenI.E. SavageJ.E. WatanabeK. BryoisJ. WilliamsD.M. SteinbergS. SealockJ. KarlssonI.K. HäggS. AthanasiuL. VoyleN. ProitsiP. WitoelarA. StringerS. AarslandD. AlmdahlI.S. AndersenF. BerghS. BettellaF. BjornssonS. BrækhusA. BråthenG. de LeeuwC. DesikanR.S. DjurovicS. DumitrescuL. FladbyT. HohmanT.J. JonssonP.V. KiddleS.J. RongveA. SaltvedtI. SandoS.B. SelbækG. ShoaiM. SkeneN.G. SnaedalJ. StordalE. UlsteinI.D. WangY. WhiteL.R. HardyJ. Hjerling-LefflerJ. SullivanP.F. van der FlierW.M. DobsonR. DavisL.K. StefanssonH. StefanssonK. PedersenN.L. RipkeS. AndreassenO.A. PosthumaD. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk.Nat. Genet.201951340441310.1038/s41588‑018‑0311‑930617256
     [Google Scholar]
  110. LozuponeM. PanzaF. Impact of apolipoprotein E isoforms on sporadic Alzheimer’s disease.Neural Regen. Res.2024191808310.4103/1673‑5374.37531637488848
     [Google Scholar]
  111. (a)Jack Jr CR, Lowe VJ, Weigand SD, et al.Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009; May 1;132(5):1355-65.10.1093/brain/awp06219339253
     [Google Scholar]
  112. (b) Ashton NJ, Leuzy A, Karikari TK, et al. The validation status of blood biomarkers of amyloid and phosphotau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging202148721405610.1007/s00259‑021‑05253‑y33677733
  113. MintunM.A. LoA.C. Duggan EvansC. WesselsA.M. ArdayfioP.A. AndersenS.W. ShcherbininS. SparksJ. SimsJ.R. BrysM. ApostolovaL.G. SallowayS.P. SkovronskyD.M. Donanemab in early Alzheimer’s disease.N. Engl. J. Med.2021384181691170410.1056/NEJMoa210070833720637
     [Google Scholar]
  114. GeorgakasJ.E. HoweM.D. ThompsonL.I. RieraN.M. RiddleM.C. Biomarkers of Alzheimer’s disease: Past, present and future clinical use.Biomark. Neuropsychiatry2023810006310.1016/j.bionps.2023.100063
     [Google Scholar]
  115. BarthélemyN.R. SalvadóG. SchindlerS.E. HeY. JanelidzeS. CollijL.E. SaefB. HensonR.L. ChenC.D. GordonB.A. LiY. La JoieR. BenzingerT.L.S. MorrisJ.C. Mattsson-CarlgrenN. PalmqvistS. OssenkoppeleR. RabinoviciG.D. StomrudE. BatemanR.J. HanssonO. Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests.Nat. Med.20243041085109510.1038/s41591‑024‑02869‑z38382645
     [Google Scholar]
  116. Study to assess the safety and biological activity of AMX0035 for the treatment of alzheimer's disease (PEGASUS).Patent NCT03533257,2021
  117. A clinical trial to determine the safety and efficacy of hope biosciences autologous mesenchymal stem cell therapy (HB-adMSCs) for the treatment of alzheimer's disease.Patent NCT04228666,2021
  118. Randomized I/​II phase study of ALZT-OP1 combination therapy in alzheimer's disease and normal healthy volunteers.Patent NCT04570644,2022
  119. AbyadehM. GuptaV. PauloJ.A. MahmoudabadA.G. ShadfarS. MirshahvaladiS. GuptaV. NguyenC.T.O. FinkelsteinD.I. YouY. HaynesP.A. SalekdehG.H. GrahamS.L. MirzaeiM. Amyloid-beta and tau protein beyond Alzheimer’s disease.Neural Regen. Res.20241961262127610.4103/1673‑5374.38640637905874
     [Google Scholar]
  120. RawatP. SeharU. BishtJ. SelmanA. CulbersonJ. ReddyP.H. Phosphorylated tau in Alzheimer’s disease and other tauopathies.Int. J. Mol. Sci.202223211284110.3390/ijms23211284136361631
     [Google Scholar]
  121. ZhangY. ChenH. LiR. SterlingK. SongW. Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future.Signal Transduct. Target. Ther.20238124810.1038/s41392‑023‑01484‑737386015
     [Google Scholar]
  122. MayeuxR. Biomarkers: Potential uses and limitations.NeuroRx20041218218810.1602/neurorx.1.2.18215717018
     [Google Scholar]
  123. KaštelanS. BrašM. PjevačN. BakijaI. TomićZ. Pjevač KeleminićN. Gverović AntunicaA. Tear Biomarkers and Alzheimer’s Disease.Int. J. Mol. Sci.202324171342910.3390/ijms24171342937686235
     [Google Scholar]
  124. TripathiT KhanH Direct interaction between the β-amyloid core and tau facilitates cross-seeding: A novel target for therapeutic intervention.Biochemistry202059434134210.1021/acs.biochem.9b01087
     [Google Scholar]
/content/journals/cprr/10.2174/0126660822329981241007105405
Loading
Correlation between Cognitive Impairment and Peripheral Biomarkers - Significance of Phosphorylated Tau and Amyloid-β in Alzheimer’s Disease: A New Insight
Curr Psyc Res Rev 22, 38 (2026); https://doi.org/10.2174/0126660822329981241007105405
/content/journals/cprr/10.2174/0126660822329981241007105405
/content/journals/cprr/10.2174/0126660822329981241007105405
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alzheimer’s disease; amyloid-β; biomarker; cognitive function; propagation; tau aggregation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test